Evidence map›Paper›PMID 37165502›Full record

ReviewCurrent molecular medicine2024

Erucic Acid: A Possible Therapeutic Agent for Neurodegenerative Diseases.

Ahsas Goyal, Nandini Dubey, Aanchal Verma, Anant Agrawal

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ahsas GoyalInstitute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.ORCID 0000-0003-0110-9238
Nandini DubeyInstitute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.ORCID 0000-0003-3758-177X
Aanchal VermaInstitute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.ORCID 0000-0002-4250-2282
Anant AgrawalInstitute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.ORCID 0000-0001-7123-4435
GLA University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodegenerative disorders are among the most common life-threatening disorders among the elderly worldwide and are marked by neuronal death in the brain and spinal cord. Several studies have demonstrated the beneficial role of dietary fatty acids in different brain disorders. This is due to their neurotrophic, antioxidant, and anti-inflammatory properties. Furthermore, extensive evidence shows that an unbalanced intake of certain dietary fatty acids increases the risk of neuropsychiatric diseases. Several research has been done on erucic acid, an ingestible omega-9 fatty acid that is found in Lorenzo's oil. Erucic acid was previously thought to be a natural toxin because of its negative effects on heart muscle function and hepatic steatosis, but it has been discovered that erucic acid is regularly consumed in Asian countries through the consumption of cruciferous vegetables like mustard and rapeseed oil with no evidence of cardiac harm. Erucic acid can also be transformed into nervonic acid, a crucial element of myelin. Therefore, erucic acid may have remyelinating effects, which may be crucial for treating different demyelinating conditions. Also, erucic acid exerts antioxidant and anti-inflammatory effects, suggesting its possible therapeutic role in different neurodegenerative disorders. Considering the fruitful effects of this compound, this article reviews the probable role of erucic acid as a pharmacological agent for treating and managing different neurodegenerative disorders.

Indexed as

Erucic AcidsNeurodegenerative DiseasesAnimalsAnti-Inflammatory AgentsAntioxidantsHumansNeuroprotective AgentsAnti-Inflammatory AgentsAntioxidantserucic acidErucic AcidsNeuroprotective Agentsadrenoleukodystrophy.Alzheimer’s diseaseErucic acidmultiple sclerosisomega-9 fatty acidParkinson’s disease

Identifiers

PMID37165502
OpenAlexW4376131129

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.